title: Corneal endothelial cell loss after mitomycin C-augmented trabeculectomy.
abstract: OBJECTIVE
  To determine the effect on the corneal endothelium of mitomycin C (MMC)-augmented trabeculectomy 3 and 12 months after surgery.
  
  
  METHODS
  In a prospective, observational clinical study, 14 eyes of 14 patients with well-established open angle glaucoma were followed for 12 months after MMC-augmented trabeculectomy. We measured the endothelial cell density, the variation in mean cell size, the percentage of hexagonal cells, and the central corneal thickness at baseline and 3 and 12 months postoperatively.
  
  
  RESULTS
  The mean endothelial cell density was 2525 [standard deviation (SD) 457] cells/mm(2) before surgery and 2332 (SD 643) cells/mm(2) and 2283 (SD 597) cells/mm(2) at 3 and 12 months after surgery, respectively, representing a cell loss of 9.5% (P=0.052) and 10.0% (P=0.027). The cell loss from 3 to 12 months was nonsignificant (P=0.40). After 12 months of follow-up, the variation in mean cell size and the percentage of hexagonal cells had not yet stabilized around the preoperative values.
  
  
  CONCLUSIONS
  Our results show that significant cell loss occurs during or immediately after MMC-augmented trabeculectomy. However, no progressive cell loss was observed from 3 to 12 months, demonstrating that MMC has no prolonged toxic effect on the corneal endothelium. From 3 to12 months after MMC-augmented trabeculectomy, active endothelial adaptations were taking place.
authors.affiliation: Department of Ophthalmology, Frederiksberg University Hospital, Frederiksberg, Denmark.
authors.forename: Thomas
authors.initials: T
authors.lastname: Storr-Paulsen
authors.forename: Jens Christian
authors.initials: JC
authors.lastname: Norregaard
authors.forename: Shakil
authors.initials: S
authors.lastname: Ahmed
authors.forename: Allan
authors.initials: A
authors.lastname: Storr-Paulsen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000963:Antimetabolites / Q000009:adverse effects*; D002452:Cell Count; D048429:Cell Size; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D004728:Endothelium, Corneal / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000601:surgery*; D006068:Gonioscopy; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects*; D011446:Prospective Studies; D014130:Trabeculectomy; D014792:Visual Acuity
chemical_list: D000963:Antimetabolites; D016685:Mitomycin